GLS and cancer: Other GLS inhibitors were also tested after manipulation of IDH1 R132H, Compound 2 or CB-839 inhibits proliferation preferentially in IDH mutated cells, but it has a poor BBB penetration [80], and compound 968 was able to sensitize cancer cells to mTOR-targeted therapies in mouse xenograft models [177].